This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AC-5216, Emapunil
Description: XBD173 is an anxiolytic and antidepressant that enhances neurosteroid biosynthesis by acting as an agonist at mitochondrial benzodiazepine receptors. The neurosteroids act on GABA A receptors. In preclinical studies, the drug avoids side effects seen with benzodiazepines acting at the plasma membrane benzodiazepine receptor, such as muscle relaxation, amnesia, and potentiation of the effects of ethanol and barbiturates.
Deal Structure: On February 12, 2002, it was announced that Dainippon had concluded an agreement to license out AC-5216 to Novartis. Under the agreement, Novartis Pharma received the exclusive rights to develop and market AC-5216 globally excluding Japan, China, Korea and Taiwan.
Partners: Sumitomo Dainippon Pharma Co., Ltd.
Additional information available to subscribers only: